Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

Research output: Contribution to journalJournal article


  • Kelly-Anne Phillips
  • Roger L Milne
  • Matti A Rookus
  • Mary B Daly
  • Antonis C Antoniou
  • Susan Peock
  • Debra Frost
  • Douglas F Easton
  • Steve Ellis
  • Michael L Friedlander
  • Saundra S Buys
  • Nadine Andrieu
  • Catherine Noguès
  • Dominique Stoppa-Lyonnet
  • Valérie Bonadona
  • Pascal Pujol
  • Sue Anne McLachlan
  • Esther M John
  • Maartje J Hooning
  • Caroline Seynaeve
  • Rob A E M Tollenaar
  • David E Goldgar
  • Mary Beth Terry
  • Trinidad Caldes
  • Prue C Weideman
  • Irene L Andrulis
  • Christian F Singer
  • Kate Birch
  • Jacques Simard
  • Melissa C Southey
  • Håkan L Olsson
  • Anna Jakubowska
  • Edith Olah
  • Anne-Marie Gerdes
  • Lenka Foretova
  • John L Hopper
View graph of relations
To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers.
Original languageEnglish
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue number25
Pages (from-to)3091-9
Number of pages9
StatePublished - 1 Sep 2013

    Research areas

  • Adult, Aged, Breast Neoplasms, Estrogen Antagonists, Female, Genes, BRCA1, Genes, BRCA2, Heterozygote, Humans, Middle Aged, Mutation, Proportional Hazards Models, Risk Factors, Tamoxifen

ID: 43049305